MOCA

BrainCheck Highlights Comprehensive Digital Cognitive Assessment Platform at MDVIP National Meeting

Retrieved on: 
Thursday, May 2, 2024
FDA, Dementia, Cognition, Documentation, Molina Healthcare, Patient, Physician, Health, NewYork-Presbyterian Queens, MDVIP, Deficit spending, Montreal Cognitive Assessment, Nursing

AUSTIN, Texas, May 2, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will highlight its comprehensive platform in booth #8 at the upcoming MDVIP National Meeting, from May 3-5, in National Harbor, MD.

Key Points: 
  • Company's next-generation tools for cognitive screening, assessment, and care planning set to empower MDVIP-affiliated physicians to enhance cognitive healthcare
    AUSTIN, Texas, May 2, 2024 /PRNewswire/ -- BrainCheck, Inc. , a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will highlight its comprehensive platform in booth #8 at the upcoming MDVIP National Meeting, from May 3-5, in National Harbor, MD.
  • "BrainCheck's technology offers a simple solution to these challenges by providing clinicians with a comprehensive set of user-friendly digital tools for cognitive screening, assessment, and care planning.
  • Trusted by hundreds of the country's most prestigious providers and specialists, BrainCheck's clinically proven platform offers a comprehensive solution streamlining screening, assessment, care planning, and monitoring.
  • BrainCheck's platform also includes Plan™, which streamlines the development and documentation of comprehensive care plans for patients with cognitive decline, post-diagnosis.

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Doctor of Philosophy, Immunotherapy, American Academy, NHS, IGNITE, Safety, University College London, AFL, TREM2, American Academy of Neurology, Microglia, Publication, Clinical professor, AAN, ALSP, MRI, Serum, CSF, Interim, Biomarker, Poster, Cerebrospinal fluid, Deficit spending, Medical imaging

WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the presentation of multiple oral and poster presentations on the Company’s lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting.

Key Points: 
  • “We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community.
  • The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP,” said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil.
  • “Both trials have led to an incredible step forward – not only in understanding ALSP disease progression, but also in drawing parallels between biomarkers and correlating clinical outcomes.
  • Data on clinical measures, biomarkers, and MRI from ILLUMINATE were presented at the conference.

BrainCheck Exhibits Comprehensive Digital Cognitive Assessment and Care Planning Platform at American Academy of Neurology 2024

Retrieved on: 
Monday, April 15, 2024
Digital technology, FDA, American Academy, Dementia, Cognition, Bon, MD, Neurology, Documentation, Patient, AAN, Caregiver, Assessment, Health, Montreal Cognitive Assessment, Nursing

AUSTIN, Texas, April 15, 2024 /PRNewswire/ -- BrainCheck, Inc., a digital health innovator delivering next-generation technology into the growing digital cognitive assessment market, will exhibit its comprehensive cognitive assessment platform in booth #834 at the American Academy of Neurology (AAN) Annual Meeting from April 13-18 in Denver, CO.

Key Points: 
  • "In an era where cognitive health is becoming increasingly central to patient care, BrainCheck's solutions offer a gateway for clinicians and facilities to bring forth a new standard in cognitive assessment and care planning," said Ms. Rodriguez.
  • Trusted by hundreds of the country's most prestigious providers and specialists, BrainCheck's clinically-proven platform offers a comprehensive solution streamlining screening, assessment, care planning, and monitoring.
  • BrainCheck has been pivotal in transforming how we approach these challenges, enhancing our efficiency and quality of care.
  • To schedule a meeting with a member of the BrainCheck team at AAN 2024, visit this link: https://calendly.com/2024-aan-annual-meeting-braincheck/meet-with-brainc... .

Creyos Health Announces Addition of Dementia Screening, Testing, and Care Planning to its Online Platform

Retrieved on: 
Tuesday, April 9, 2024
Western University, Diagnosis, AMGA, Research, Dementia, Prevalence, Entrepreneurship, Deficit spending, Disease, Caregiver, Patient, American Medical Group Association, OBE, Doctor of Philosophy, Statistics, MCI, Cognition

This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.

Key Points: 
  • This protocol, now available in the Creyos platform, is the result of 30 years of rigorous research and scientific validation.
  • It offers full spectrum cognitive care, from early detection of mild cognitive impairment, to testing for an accurate dementia diagnosis, followed by tailored care planning, and ongoing longitudinal monitoring.
  • Dementia testing includes four additional tasks and behavioral health questionnaires, aligned with DSM-5 diagnostic criteria for dementia.
  • “We started Creyos because we noticed a significant gap in how cognitive health was being addressed,” said Marc Lipton, Co-Founder and CEO of Creyos.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Administration, CSF1R, TREM2, MRI, Data analysis, PD, CSF, Magnetic resonance imaging, Patient, Biomarker, Microglia, Osteopontin, Fluid mechanics, IGNITE, Investment, Clinical trial, Pharmacokinetics, Interim, Research and development, Data, FDA, AFL, Pharmaceutical industry

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Flash News: OKX Wallet and Mocaverse Partnership Unlocks Exclusive Opportunities for Users

Retrieved on: 
Wednesday, February 28, 2024
Culture, Growth, Animoca Brands, Web3, OKX, Blockchain, Ecosystem, Partnership

OKX Wallet has entered into a strategic partnership with Mocaverse , a tokenized layer of the Web3 culture and entertainment ecosystem.

Key Points: 
  • OKX Wallet has entered into a strategic partnership with Mocaverse , a tokenized layer of the Web3 culture and entertainment ecosystem.
  • Central to this partnership is the exclusive opportunity for OKX Wallet users to claim Moca IDs , the decentralized identity that offers access to over 450 projects in Animoca Brands' portfolio, without the need to hold a Moca NFT or referral code.
  • OKX Wallet users are invited to take advantage of this unique opportunity and become part of the evolving Mocaverse community.
  • Further details on how OKX Wallet users can claim Moca IDs can be found here .

POTUS Cognitive Test Creators Introduce MoCA-XpressO for Public Use

Retrieved on: 
Wednesday, February 21, 2024
Alzheimer's disease, FDA, Ageing, Cognition, Disease, Deficit spending, Motivation, Diagnosis, MCI

For the public concerned with their cognitive performance, or that of a loved one, MoCA Cognition offers the scientifically validated "XpressO by MoCA" app—a rapid cognitive self-assessment tool that can predict performance on the MoCA Test and suggest when to consult with a healthcare professional.

Key Points: 
  • For the public concerned with their cognitive performance, or that of a loved one, MoCA Cognition offers the scientifically validated "XpressO by MoCA" app—a rapid cognitive self-assessment tool that can predict performance on the MoCA Test and suggest when to consult with a healthcare professional.
  • The XpressO by MoCA app was developed in response to growing needs of primary care to detect cognitive impairment, quickly and accurately.
  • This is particularly important considering our aging population, limited public care resources, and new Alzheimer's Disease treatments coming available.
  • Validation studies have demonstrated an approximately 85% accuracy in predicting a MoCA score in the mild cognitive impairment (MCI) range.

Combining Fiber and FWA extension technology is key to bridging the digital divide, says InCoax

Retrieved on: 
Tuesday, February 20, 2024
Element management, FWA, Wireless, Investment, MDU, Data-rate units, Risk, Home, CSP, Telephone, Control, Digital divide, NTE, CAPEX, Modem, NTIA, Cable television

While the spotlight has been on fiber, the reality is that fiber alone cannot address the monumental challenge of connecting all Americans.

Key Points: 
  • While the spotlight has been on fiber, the reality is that fiber alone cannot address the monumental challenge of connecting all Americans.
  • A combination of fiber and FWA networks is essential to serve urban and rural areas effectively.
  • The development of FWA technology has been monumental in recent years, paving the way for high-performance multigigabit broadband connectivity services.
  • For the past four years, InCoax has delivered FWA Extension to thousands of MDUs in the US.

Combining Fiber and FWA extension technology is key to bridging the digital divide, says InCoax

Retrieved on: 
Tuesday, February 20, 2024
Element management, FWA, Wireless, Investment, MDU, Data-rate units, Risk, Home, CSP, Telephone, Control, Digital divide, NTE, CAPEX, Modem, NTIA, Cable television

While the spotlight has been on fiber, the reality is that fiber alone cannot address the monumental challenge of connecting all Americans.

Key Points: 
  • While the spotlight has been on fiber, the reality is that fiber alone cannot address the monumental challenge of connecting all Americans.
  • A combination of fiber and FWA networks is essential to serve urban and rural areas effectively.
  • The development of FWA technology has been monumental in recent years, paving the way for high-performance multigigabit broadband connectivity services.
  • For the past four years, InCoax has delivered FWA Extension to thousands of MDUs in the US.

Presidents' Cognition and Appropriate Use of the MoCA Test Content

Retrieved on: 
Tuesday, February 13, 2024
Administration, Cognition, Certification, Patient

The MoCA Test is a copyrighted work owned by MoCA Cognition.

Key Points: 
  • The MoCA Test is a copyrighted work owned by MoCA Cognition.
  • The MoCA Test cannot be reproduced, or distributed, in whole or in part, by others, including the media, without express permission from MoCA Cognition.
  • The MoCA Test was designed and explicitly meant only for use by healthcare professionals to assess their patients.
  • Administration, scoring and interpretation of the MoCA Test are reserved to healthcare professionals and require specific training and certification.